In conclusion, our study demonstrates for the first time the feasibility of using inhibitors of the helicase-binding site of DDX3X not only as broad-spectrum antivirals but also as new potent broad-spectrum targeted anticancer compounds that are active against difficult to treat tumors such as GBM. The gene discussed is DDX3X; the disease is glioblastoma.